Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

Published:2021-08 Issue:8 Volume:24 Page:1118-1125
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Patel Dony,Grimson Fiona,Mihaylova Elena,Wagner Peter,Warren Joss,van Engen Anke,Kim Joseph

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference25 articles.

1. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research;Moloney;Int J Technol Assess Health Care,2015

2. Orphan drugs and their impact on pharmaceutical development: [published correction appears in Trends Pharmacol Sci. 2018;39(12):1077];Attwood;Trends Pharmacol Sci,2018

3. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties;Pontes;Orphanet J Rare Dis,2018

4. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review;Goring;BMJ Open,2019

5. A 25-year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review;Beaver;JAMA Oncol,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey;Value in Health;2024-07

2. Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space;Pharmaceutical Statistics;2024-06-25

3. Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance;Journal of Market Access & Health Policy;2024-05-20

4. Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps;Value in Health;2024-05

5. Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries;Future Oncology;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3